Translate
Ronny Allan
Introduction
I found these 10 short video series from OncLive very useful. Each video ranges from 2 – 5 minutes long and is very easy to watch and digested. Not only a succinct primer on (so-called) carcinoid syndrome but also an update on the evolving approaches. And the series also includes information on Hedinger Syndrome (carcinoid heart disease) which can be caused by the effects of this syndrome.
The panel includes some ‘big hitter’ names in our scientific community including:
Satya (Nanu) Das, MD, MSCI (Oncologist)
Jerome Zacks, MD (Cardiologist)
Rodney Pommier, MD (Surgeon)
Video list (click on the blue link to watch each one)
Episode 1 – Overview of Neuroendocrine Tumors (NETs) (onclive.com)
Episode 2 – Overview of Carcinoid Syndrome (CS) (onclive.com)
Episode 3 – Overview of Carcinoid Heart Disease (CHD) (onclive.com)
Episode 4 – Management of Carcinoid Syndrome-Related Symptoms (onclive.com)
Episode 5 – Diagnosis and Management of Somatostatin Analog-Refractory Carcinoid Syndrome (onclive.com)
Episode 6 – Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome (onclive.com)
Episode 7 – Data from the TELEPATH Trial and Real-World Analyses (onclive.com)
Episode 8 – Prevention, Treatment, and Management of Carcinoid Heart Disease (onclive.com)
Episode 9 – Unmet Needs for Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome (onclive.com)
The Syndromes of Neuroendocrine Cancer – Early signs of a Late Diagnosis?
Carcinoid syndrome is only one of several hormonal syndromes involved, read about the others here.
Neuroendocrine Cancer – don’t break my heart
My compendium of information contains more detail on Hedinger Syndrome (carcinoid heart disease).
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity. Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click on the picture:
Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Neuroendocrine Cancer Clinical Trial – Lutetium-177Lu (Satoreotide)
What is Satoreotide? It’s an agonist treatment. i.e. a ‘next generation’ radiologand for Peptide receptor radionuclide therapy (PRRT) or more specifically the radiopharmaceutical that binds
A review of September 2023 on RonnyAllan.NET – Living with Neuroendocrine Cancer
On my website RonnyAllan.NET, September was an interesting month because I had pushed out some blogs before I went on a planned overseas holiday from
Never mind the Bollocks – here’s the cancer
I don’t tend to share some very personal stuff, but this is on the boundary of that rule and there are some important messages to
First and only FDA-cleared, fully automated chromogranin A assay
There has been controversy about the utility of Chromogranin A for many years now. Specialists have been critical about its use but to be fair
Neuroendocrine Cancer: Question, Clarify, Confirm
One of the many observations I make in my private Neuroendocrine Cancer Facebook group is the misunderstandings caused by the use of non-standard terminology combined
Clinical Trial – Lutathera NETTER-2 Important Update
UPDATE – Sep 25th, 2023 – Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors
Lanreotide: Ipsen injection devices vs generic injection devices
Whenever I get a chance to talk to a pharma involved in somatostatin analogue injection devices, I tell them one very important thing …… “To
Cancer doesn’t take holidays (but I do)
Glen Etive Scotland in 2018 After diagnosis in July 2010, with the exception of a planned holiday to Turkey prior to my ‘big surgery’, holidays
Update from Ronny Allan: No evidence of progressive disease at any site
Update August 2023. Latest CT surveillance scan reports “No evidence of progressive disease at any site”. Very pleased! With incurable but treatable cancers such as
